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Background: Sub-Saharan African (SSA) countries are experiencing rapid transitions with increased life expectancy.
As a result the burden of age-related conditions such as neurodegenerative diseases might be increasing. We
conducted a systematic review of published studies on common neurodegenerative diseases, and HIV-related
neurocognitive impairment in SSA, in order to identify research gaps and inform prevention and control solutions.
Methods: We searched MEDLINE via PubMed, ‘Banque de Données de Santé Publique’ and the database of the ‘Institut
d’Epidemiologie Neurologique et de Neurologie Tropicale’ from inception to February 2013 for published original studies
from SSA on neurodegenerative diseases and HIV-related neurocognitive impairment. Screening and data extraction
were conducted by two investigators. Bibliographies and citations of eligible studies were investigated.
Results: In all 144 publications reporting on dementia (n = 49 publications, mainly Alzheimer disease), Parkinsonism
(PD, n = 20), HIV-related neurocognitive impairment (n = 47), Huntington disease (HD, n = 19), amyotrophic lateral
sclerosis (ALS, n = 15), cerebellar degeneration (n = 4) and Lewy body dementia (n = 1). Of these studies, largely based
on prevalent cases from retrospective data on urban populations, half originated from Nigeria and South Africa. The
prevalence of dementia (Alzheimer disease) varied between <1% and 10.1% (0.7% and 5.6%) in population-based
studies and from <1% to 47.8% in hospital-based studies. Incidence of dementia (Alzheimer disease) ranged from 8.7
to 21.8/1000/year (9.5 to 11.1), and major risk factors were advanced age and female sex. HIV-related neurocognitive
impairment’s prevalence (all from hospital-based studies) ranged from <1% to 80%. Population-based prevalence of PD
and ALS varied from 10 to 235/100,000, and from 5 to 15/100,000 respectively while that for Huntington disease was
3.5/100,000. Equivalent figures for hospital based studies were the following: PD (0.41 to 7.2%), ALS (0.2 to 8.0/1000),
and HD (0.2/100,000 to 46.0/100,000).
Conclusions: The body of literature on neurodegenerative disorders in SSA is large with regard to dementia and
HIV-related neurocognitive disorders but limited for other neurodegenerative disorders. Shortcomings include few
population-based studies, heterogeneous diagnostic criteria and uneven representation of countries on the continent.
There are important knowledge gaps that need urgent action, in order to prepare the sub-continent for the anticipated
local surge in neurodegenerative diseases.
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Worldwide, populations are increasingly living longer in-
cluding in developing countries, where the largest num-
ber of elderly people is currently found. In sub-Saharan
Africa (SSA) (Figure 1), life expectancy at birth has in-
creased by about 20 years between 1950 and 2010 [1].
During this same period, while the proportion of people* Correspondence: andre.kengne@mrc.ac.za
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unless otherwise stated.aged 60 years and above has remained constant at
around 5%, the absolute number in this group has in-
creased by about four folds from 9.4 million in 1950
(total population 179.5 million) to 40.3 million in 2010
(total population 831.5 million). In general, population
ageing has been described as a more recent phenome-
non in SSA, causing figures for this region to be well
below the global average [1]. However, projections sug-
gest that the gap in life expectancy between SSA and the
world average, which was around 20 years in 2010, will
drop to 10 years by 2050. By this time, about 7.6% of theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2458/14/653SSA population (estimated total 2.074 billion) will be
aged 60 years and above, which in absolute number will
translate into four times the 2010 estimates, and corres-
pond approximately to 156.7 million people [2].
Population ageing is considered a global public health
success, but also brings about new health challenges in
the form of chronic diseases including cardiovascular
diseases, cancers, as well as neurodegenerative disorders.
A characterization and updated picture of the latter con-
ditions in SSA is particularly important in view of a) the
ongoing demographic transition and the resulting surge
in the prevalence of neurodegenerative diseases in SSA;
b) the successful roll-out of antiretroviral therapies inMAURITANIA
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Figure 1 Sub-Saharan African countries.the region and the potential, yet unknown impact of
long-term survival with HIV infection and related treat-
ments on the occurrence of neurodegenerative disorders
[3]; and c) lastly, the need for reliable data for health
service planning. Recently, there have been efforts to
summarize existing data for conditions like Parkinson
disease (PD) [4,5] dementia [6,7] or amyotrophic lateral
sclerosis [8], but not for other common neurodegenera-
tive disorders, while there are suggestions of possible
African distinctiveness in their occurrence and features [9].
We systematically reviewed the published literature on
common neurodegenerative disorders and HIV-related
neurocognitive impairment among sub-Saharan Africans,D
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as clinical and public health implications.
Methods
Data sources
We searched MEDLINE via PubMed, and the French
database ‘Banque des Données en Santé Publique’ (BDSP
www.bdsp.ehesp.fr) for articles published until February
2013. In addition we searched the database of the ‘Institut
d’Epidemiologie Neurologique et de Neurologie Tropicale’
(IENNT). We used a combination of relevant terms to
search (in English for PubMed and in French for BDSP
and IENNT), which are presented in Additional file 1 (ex-
cept for IENNT searches for which we used ‘neuroepide-
miologie’ and other themes referring to neurodegenerative
diseases). Two evaluators (AL and JBE) independently
identified articles and sequentially (titles, abstracts, and
then full texts) screened them for inclusion (Figure 2). For
articles without abstracts or without enough information
in the abstract to make a decision, the full text, and where11_
4049 Citations identified through MEDLINE (4036) t
(23) and the IENT)
214 Full-text articles read
144 studies included 
337 Abstracts of potentially relevant articles 
reviewed 
1641 Titles/Abstract screened 
5 articles from 
hand search of 
neurological 
journals in 
SSA
Figure 2 Flow of selection of studies for inclusion.necessary supplemental materials, were reviewed before
a decision was made. We supplemented the electronic
searches by scanning the references lists of relevant
publications, and identifying their citations through the
ISI Web of Science, and by hand-searching all issues of
the African Journal of Neurological Sciences. Disagree-
ments were solved by consensus or review by a third
investigator (APK).
Study selection
We included studies conducted in a country of the SSA
region (Figure 1) that reported on the following neurode-
generative diseases among adults: Alzheimer’s disease,
fronto-temporal dementia, Lewy body dementia, vascular
dementia, cortico-basal degeneration, multi system atro-
phy, Parkinson’s disease (PD), amyotrophic lateral scler-
osis (ALS), Huntington disease, cerebellar degeneration,
and HIV-related neurocognitive impairment. We made no
restriction by study design. We excluded duplicate publi-
cations, review articles, studies conducted exclusively inhe BSD 
119 abstracts excluded:
- 36 on studies not conducted in SSA
- 34 not referring to neurodegenerative 
disorders 
- 28 review articles 
- 22 articles not found
- 2 experimental studies 
- 1 article on a study conducted in children
75 articles excluded: 
- 69 articles not containing epidemiological 
data on neurodegenerative disorders 
- 3 letters/commentaries
- 3 not including data from SSA
65 Articles from citations scanning 
2474 Articles excluded (duplicates)
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migrant populations of African descent living out of the
continent. Figure 2 shows the study selection process.
We provide a rigorous appraisal of the overall data
and the epidemiological studies in particular, and make
recommendations regarding future approaches to meas-
urement, notwithstanding the challenges involved in
such undertakings.
Data extraction, assessment, and synthesis
Two reviewers (AL and JBE) independently conducted
the data extraction from included studies. We extracted
data on study settings, design, population characteristics,
measures of disease occurrence (incidence and/or preva-
lence), and risk factors for the various conditions exam-
ined. Given the diversity of neurodegenerative pathologies
and the heterogeneity of populations assessed, we did not
use a particular framework for the assessment of the qual-
ity of studies. However, whenever population-based
studies and hospital-based studies had been conducted for
a condition, we relied more on the conclusions of
population-based studies to address relevant questions,
and appropriately reported the results. We conducted a
narrative synthesis of the evidence.
Results
The study selection process is shown in Figure 2. A total
of 4049 citations were identified through MEDLINE, the
IENNT database and BDSP searches; 337 abstracts were
evaluated in detail and 214 full-text publications re-
viewed. The final selection included 144 publications
reporting on Parkinsonism (20 studies), dementia (49
publications), HIV-related neurocognitive impairment
(47 publications), Huntington disease (19 studies), amyo-
trophic lateral sclerosis (15 studies), cerebellar degener-
ation (4 studies) and Lewy body dementia (1 study).
These studies were published between 1955 and 2012,
with about 50% conducted in only two countries: Nigeria
and South Africa.
Parkinson disease, other Lewy body diseases and
fronto-temporal dementia
Twenty studies reported on Parkinsonism (Table 1), in-
cluding five community-based and sixteen hospital-
based. Four were case–control in design and all the
others were cross-sectional studies, including reviews of
medical records. These studies were conducted in seven
countries including Nigeria (ten studies), South Africa
(four studies), Tanzania (two studies), Ethiopia, Ghana,
Cameroon and Zimbabwe (one studies each). The number
of participants with PD ranged from two to 32 and the
prevalence from ten to 235/100,000 in community-based
studies. The number of participants with Parkinsonism
ranged from four to 397, and the prevalence ofParkinsonism varied from 0.41 to 7.2% of neurological ad-
missions/consultations in hospital-based studies. The pro-
portion of men among those with PD ranged from 53 to
100%, and age ranged from 30 to >100 years. Age at the
clinical onset of the disease ranged from 17 to 90 years.
The clinical types of the disease were largely dominated
by Parkinson disease (38 to 100%).
The most commonly used tool to diagnose PD was the
UKPDS Brain bank criteria and population-based (hos-
pital-based) prevalence for the studies that applied those
criteria ranged from 40 to 235/100,000 (11 to 69.4/1,000
neurological consultations). In general risk factors were
not investigated across studies, although one study
found that 38% of patients with Parkinsonism had ath-
erosclerosis and 8% had encephalitis [18].
We found three cases of Lewy body dementia in a
retrospective study in Nigeria, and one case in a retro-
spective study in Senegal representing respectively 1.2/
100,000 of admission over a period of 10 years [30] and
7.5/1000 of participants in a specialized memory clinic [31].
The prevalence of fronto-temporal dementia has been
reported in two hospital-based studies conducted in
Neuropsychiatric clinics in Nigeria (prevalence rate: 1.7/
100,000 of all admissions) and in Senegal (prevalence
rate: 7.5/1000 of all participants evaluated for memory
impairment) [30,31].
Dementia
(Table 2) summarizes the 49 publications that re-
ported on dementia. These include 18 hospital-based,
30 community-based publications and one publication
from a nursing home. Two were case–control in design,
seven were cohort-studies and 40 were cross-sectional, in-
cluding two autopsy studies. These publications reported
on studies conducted in eleven countries: Nigeria (33 pub-
lications), Senegal (four publications), Kenya and Tanzania
(three publications each), Benin, Central African Republic,
Congo republic, (two publications each), South Africa,
Cameroon and Zambia (one publication each). In addi-
tion, there were seven publications on multicenter
studies including African American participants in the
USA and participants from African countries [32-37].
The overall study size varied from 56 to 2494 in
community-based studies and from 23 to 240,294 in
hospital-based investigations. The prevalence of de-
mentia ranged from <1% to 10.1% in population-based
studies [32,34-57] and from <1% to 47.8% in hospital-
based studies [16,21,30,33,38,58-69].
The proportion of men among those with dementia
was 7.1 to 69.1%. The mean age of participants ranged
from 70.1 to 83.8 years. When provided, age at clinical
diagnosis of disease ranged from 80.7 to 83.8 years.
Alzheimer disease was the most common form of the
disease, representing 57.4 to 89.4 % of all cases
Table 1 Overview of studies on Parkinsonism and risk factors in sub-Saharan African countries
Author, year of
publication
Country Setting Design/period
of study
Population characteristics Diagnosis criteria Prevalence Profile of
parkinsonism
patients
Comments
Bower [10],
2005
Ethiopia Hospital Cross-sectional
2003-2004
720 patients; 109 (15 · 1%)
with movement disorders
including 71 men; age 52 y.
(13–80)
Not provided 72/1,000 of all
admissions
(PD: 64/1,000)
N:52; PD:88% Review of medical files/
outpatient neurology clinic.
Age (at onset):
57y (30–80)
Men: 75%
Akinyemi [11],
2008
Nigeria Hospital Case–control
2005-2005
51 patients (men 37) with
PD and 50 controls
UKPDS Brain Bank
criteria
NA N:51; PD: 100% 22% patients with PD had
cognitive dysfunction, with
age at PD onset as sole
predictor of cognitive
dysfunction.
Age (at onset):
70y (41–80)
Men:72%
Cosnett [12],
1988
South
Africa
Hospital Cross-sectional
1979-1985
2638 patients Clinical (Bradykinesia,
rigidity, resting tremor
and postural instability)
5.3/1,000 N:14; PD: 100% Retrospective review of
medical files/outpatient clinic
Age: NA Blacks: 1.5/1000
Men: NA Indians: 12.6/1000
Whites: 23.1/1000
Dotchin [13],
2008
Tanzania Community Cross-sectional 161,071 inhabitants UKPDS Brain Bank
criteria
Overall: 40/100,000 N: 32; PD:100% Prevalence is adjusted to
UK population. Mean
duration 5.1 yMen: 64/100,000
women: 20/100,000 Age (at onset):
69y (29–90)
Men: 72%
Schoenberg
[14], 1988
Nigeria Community Cross-sectional Black population aged
40 + 3412 participants
Clinical Age adjusted:
67/100,000
N: 2; PD:100%
Age: NA
Men: NA
USA Community Cross-sectional Black population aged
40 + 3521 black
participants and 5404
white participants.
Clinical Age adjusted: N: 12; PD: 100%
Age: NA
Blacks: 341/100,000 Men: NA
Whites: 352/100,000
Winkler [15],
2010
Tanzania Hospital Cross-sectional n = 8676 patients admitted
(740 with neurological
diseases)
UKPDS Brain Bank
criteria
1/1,000 (all patients) N: 8; PD:37%
2003 11/1,000 (Patients
with neurological
diseases
Age: ≥32 y
Men: 100%
Community Cross-sectional 1569 people, age
50–110 years
UKPDS Brain Bank
criteria
235/100,000 N: 0 None of the 18 screened-
positive was confirmed as
having PD. Poisson
distribution used to
estimate the prevalence.
2003-2005
Cameroon Hospital Cross-sectional Not provided N: 41; PD 100%
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Table 1 Overview of studies on Parkinsonism and risk factors in sub-Saharan African countries (Continued)
Kengne [16],
2006
4041 patients in a
neurology clinic145 (3.9%)
had neurodegenerative
diseases
488/1,000 of all
neurodegenerative
diseases; 10.1/1,000
of all neurologic
consultation
4 selected neurodegenerative
brain disorders: dementia, PD,
ALS, chorea
1993-2001 Age: 15-84 y
Men: 73.2%
Lombard
[17],1978
Zimbabwe Hospital Cross-sectional Total patients admitted:
83,453 blacks, 34,952 whites
Not provided Blacks: 0.21/1,000 N: 50 (17 blacks) Retrospective review of
medical files
Whites: 2.83/1,000 Age/men: NA
Osuntokun [18],
1979
Nigeria Hospital Cross-sectional 217 patients with parkinsonism Not provided NA N: 217; PD 38% All patients evaluated by
the authors
1966-1976 Age: median
51-70 y,
Men:75%
Osuntokun [19],
1987
Nigeria Community Cross-sectional Total participants surveyed:
18,954
Not provided 10/100,000 N. 2; PD 100% Screening Questionnaire
developed by author
1985 Age/men: NA
Haylett [20],
2012
South
Africa
Hospital Cross-sectional 229 patients with PD including
163 whites (71%), 45 mixed
ancestry (20%), 17 blacks
(7%) and 4 Indians (2%)
UKPDS Brain Bank
criteria
NA N: 229; PD 100% Mutation in the Parkin gene
Age (at onset):
54 y (17–80)
Homozygous or compound
heterozygous mutations:
7 patients
Heterozygous variant: 7Men: % NA
Ekenze [21],
2010
Nigeria Hospital Cross-sectional 8440 admission in the
medical ward; 1249 had
neurological diseases
(men 640)
Not specified 21.9/1000 of al
neurological
admissions
N: 14
2003-2007 Age≥ 70 y (71%)
Men: 28.6%
Owolabi [22],
2010
Nigeria Hospital Cross-sectional 6282 admission in the
medical ward; 980 had
neurological diseases
(men 586)
Clinical: any 3 out of
tremor, rigidity, Akinesia/
bradikinesia/postural
and instability
4.1/1,000 of all
neurological
admissions
N: 4
2005-2007 Age: (50–68)
Men; 100%
Okubadejo [23],
2004
Nigeria Hospital Case–control 33 participants (men 25,
mean age 60 y) with PD
and 33 match controls
Any 3 out of tremor,
rigidity, Akinesia/
bradikinesia/postural
and instability
NA N: 33 Case fatality rate was higher
in PD (25% vs. 7.1%), Factors
associated with increased
mortality: advanced age and
disease severity
Age (at onset):
36-80y
Men: 75%
Okubadejo [24],
2005
Nigeria Hospital Case–control 28 participants (men 21,
mean age 63 y) with PD
and 28 match controls
Any 2 out of tremor,
rigidity, Akinesia/
bradikinesia/postural
and instability, exclusion
of other causes
of parkinsonism
NA N: 28; PD 100% Autonomic dysfunction rate
was higher in PD (61% vs. 6%),
Age (at onset):
37-76 y
Men: 76%
Okubadejo [25],
2010
Nigeria Hospital Cross-sectional 124 participants with
Parkinsonism in a
neurology clinic
Any 3 of the following:
tremors, rigidity,
bradykinesia, and
postural or gait
abnormality
15/1,000 of all
neurological
consultations
N: 98; PD 79% Other causes of parkinsonism
n(%): Vascular/drug
induced/MSA/LBD: 9(35)/5
(19)/4(15)/3(11)
1996-2006 Age (at onset):
61y Men: 76.5%
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Table 1 Overview of studies on Parkinsonism and risk factors in sub-Saharan African countries (Continued)
Keyser [26],
2010
South
Africa
Hospital Cross-sectional 154 patients with PD
including 51 whites (35%),
45 Afrikaners (31%), 29 mixed
ancestry (20%), 17 blacks
(12%) and 3 Indians (2%).
UK Parkinson’s Disease
UKPDS Brain Bank criteria
NA N: 154; PD 100% 16 sequence variants of the
PINK1gene identified: 1
homozygous mutation (Y258X),
2 heterozygous missense
variants (P305A and E476K),
and 13 polymorphisms
Age (at onset): 52 y
Men: 62%
Van Der Merwe
[27], 2012
South
Africa
Hospital Cross-sectional 111 patients with early onset
PD (men 71) and 286 with
late onset PD (men 62%)
from a movement
disorder clinic
UKPDS Brain Bank
criteria
NA N: 397; PD 100% A positive family history was
associated with a younger
age at onset.2007-2011 Age (at onset):
57 y Men: 248
Femi [28], 2012 Nigeria Hospital Cross-sectional 1153 participants in 2
Neurologic clinics; 96
(men: 74) had
parkinsonism
presence of at least three
of the four cardinal features
of tremors, rigidity,
bradykinesia, and postural
or gait abnormality
69.4/1,000 of all
neurological
consultations
N: 96; PD (83.3%)
2007-2011 Age: 58 y
Men: 63.5%
Cilia [29], 2012 Ghana Hospital Case–control 54 participants with
PD and 46 healthy
participants
UKPDS Brain Bank
criteria
NA N: 54; PD 100% Leucine-rich repeat kinase 2
(LRRK2) gene found in no
participantsAge (at onset):
59 y (30–83)
Men: 61%
NA: Not available; PD: Parkinson’s disease; UK: United Kingdom; USA: United States of America; y: years.
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa
Author, year
of publication
Country/setting Design/period
of study
Population characteristics Diagnostic criteria Incidence Prevalence (%) Risk factors
Lambo [58],
1966
Nigeria Retrospective/
Cross-sectional,
1954-1963
328 participants (26% ≥60 y.) Not provided NA Senile dementia*: NA
Hospital Overall: 26%, Men:
18.9% Women: 30.5%
75 cases of dementia (21 men)
Ben-Arie [39],
1983
South Africa Cross-sectional,
1982
139 participants aged ≥65 y. MMSE/ICD-8 codes NA Any (severe) dementia
8.6% (3.6%)
NA
Community
Makanjuola [59],
1985
Nigeria Cross-sectional
1979-1982
51 (5.2% of new consultations);
age ≥60 y.
ICD-9 codes NA Dementia 11.2% NA
Hospital
Gureje [60],
1989
Nigeria Cross-sectional,
1984
1914 patients; ICD- 9 codes NA No case of dementia NA
Community
Ogunniyi [40],
1992
Nigeria Cross-sectional 930 participants; age ≥40 y.
(293 aged ≥65 y.); No case
of dementia
DSM-III-R criteria NA No case of dementia NA
Community
Osuntokun [61],
1994
Nigeria, hospital
Autopsy study
Cross-sectional
1986- 1987
111 brains autopsied including
85 patients aged ≤60 y.
Beta A4 amyloid on
brain tissues
NA Heavy/moderate/mild
plaque load: 0/6.3/18.9%
NA
Osuntokun [41],
1995
Nigeria,
community
Cross-sectional 56 subjects (17 with dementia
and 12 with AD); age ≥65 y.
Dementia –CSID NA APOE ε4 allele in
dementia/AD/controls
17.6/16.7/20.5%.
NA
AD - NINCDS-ADRDA
criteria
Osuntokun [38],
1995
Nigeria, hospital
Autopsy study
Cross-sectional 198 brains were autopsied senile plaque,
neurofibrillary tangle,
and amyloid vascular
degeneration
NA No evidence of NFT or
senile plaque
NA
1986- 1987 Including 45 (23%) ≥65 year
Hendrie [32],
1995
Nigeria,
community
Cross-sectional 2494 participants, age ≥65 y.,
Dementia −28, AD - 18, VaD - 8.
Dementia: CSID/DSM-III-
R/ICD-10/AD: NINCDS-
ADRDA criteria
NA Dementia - Overall/
65-74/75-84/≥85 y:
1992-1993 2.3/0 · 9/2.7/9.6;
AD - 1.4/0.5/1.7/5.9%
Indianapolis-USA,
community &
nursing home
Cross-sectional 2212participants, aged ≥65 y.
(community) and 106
(nursing home)
Dementia: CSID/DSM-III-
R/ICD-10/AD: NINCDS-
ADRDA criteria
NA Dementia Overall/
65-74/75-84/≥85 y:
NA
1992 - 1993
8.2/2 · 6/11.4/32.4%
AD −6.2/1.6/8.0/28.8%
Ogeng'o [33],
1996
Tanzania, hospital Cross-sectional 12 Non-demented subjects
aged 45–83 y.
senile plaque,
neurofibrillary tangle,
and cerebral amyloid
angiopathy
NA Amyloid β plaques:17% NA
1996 Autopsy study Neurofibrillary Tangles:
17%; Cerebral Amyloid
angiopathy: 17%
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Kenya, hospital Cross-sectional
Autopsy study
20 Non-demented subjects
aged 45–70 y.
Senile plaque,
neurofibrillary tangle,
and cerebral amyloid
angiopathy
NA Amyloid β plaques: 15%;
Neurofibrillary Tangles:
15%; Cerebral Amyloid
angiopathy: 15%
NA
USA-Cleveland,
Hospital
Cross-sectional/
Autopsy study
20 Non-demented subjects
aged 48–84 y.
Senile plaque,
neurofibrillary tangle,
and cerebral amyloid
angiopathy
NA Amyloid β plaques:
20%; Neurofibrillary:
15%; Cerebral Amyloid
angiopathy: 20%
NA
Ogunniyi [42],
1997
Nigeria,
community
Cross-sectional 2494 participants aged >65 y
screened, 28 with dementia.
Screening: CSI-D) NA Any/ AD/ vascular
dementia - 1.1/0.7/0.3%
N A
1992-1994 Dementia: DSM-III-R
and ICD-10 codes
AD: NINCDS-ADRDA
Sayi [62], 1997 Tanzania, hospital Cross-sectional 24 demented and 286
non-demented participants
aged 50–89 y.
Swahili modified MMSE NA Prevalence of ε4 allele of
APOE: Demented - 25%;
non demented - 21%
NA
Kenya, hospital Cross-sectional 22 demented and 60
non-demented participants
aged ≥65 y.
Swahili modified MMSE NA Prevalence of ε4 allele of
APOE: Demented - 42%,
non-demented - 27%
NA
Baiyewu [63],
1997
Nigeria, Nursing
home
Cross-sectional 23 participants (in a nursing
home) aged 66–102 y.;
11 women
DSM-III-R/AGECAT NA Any dementia (AD) -
47 · 8% (26 · 1%)
NA
1994
Hall [34],1998 Nigeria,
community
Case–control 2494 participants; age ≥ 65 y.; Screening: CSID NA 18 cases of possible or
probable AD1.4%
age (OR = 1.15;
95%
423 clinically assessed
after screening, CI = 1.12-1.18)
and female gender
(OR = 13.9; 95%
CI = 3.85-50.82)
Dementia: DSM-III-R/ICD-
10/AD: NINCDS-ADRDA
USA–Indianapolis,
community
Case–control 2212 participants; age ≥ 65 y.; Screening: CSID NA Possible/probable
AD 6.2%
age, family history
of dementia, education;
rural residenceDementia: DSM-III-R/ICD-
10/AD: NINCDS-ADRDA
351 clinically assessed after
screening,; 49 (men 17)
diagnosed with AD
Uwakwe [70],
2000
Nigeria, Hospital Cross-sectional 119 participants; age ≥65 y;
3 had dementia
Geriatric Mental State
and/ICD-10
NA 2.8% NA
1995-1996
Ogunniyi
[43], 2000
Nigeria,
community
Cross-sectional
1992-1994
2494 participants, age ≥65 y.;
28 with dementia (men: 8)
including 18 with AD, 8 with
vascular dementia
Screening: CSID NA Any dementia 2.3% Age (OR: 1.15), female
gender (13.9), living
with others (OR: 0 · 06)Dementia: DSM-III-R/ICD-10
AD: NINCDS-ADRDA AD: 1.4%
E4 allele in AD (normal
subjects) 34.2% (21.8%)
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Indianapolis-USA,
community
Cross-sectional 2212 participants, age ≥65 year;
65 with dementia including
49 with AD, 10 with
vascular dementia
Screening: CSID NA Dementia (AD) overall/
65-74/75-84/≥85 y – 8.2
(6.2)/2.62 (1.58)/ 11.4
(8.0)/32 · 4% (28.8%);
Age, rural residence,
family history of
dementia, educationDementia: DSM-III-R/ICD-101992-1994
AD: NINCDS-ADRDA
Hendrie [35],
2001
Nigeria,
community
Prospective cohort
Baseline survey
in 1992-1993
2459 participants included
after the first visit; 1303
(men 461) completed the
follow-up; age ≥65 y.
Screening: CSID Dementia:
13.5/1,000
NA NA
Dementia: DSM-III-R/ICD-10
AD: NINCDS-ADRDA AD: 11.5/1000
USA-Indianapolis,
community
Prospective cohort 2147 African-Americans
included after the first
visit; 1321 (men 417)
completed the follow-up;
age ≥65 y.
Screening: CSID Dementia (AD) NA NA
Baseline survey
in 1992-1993
Dementia: DSM-III-R/ICD-
10/AD: NINCDS-ADRDA
32.4/1,000
(25.2/1,000)
Baiyewu [44],
2002
Nigeria,
community
Prospective cohort
baseline survey
in 1992-1993
2487 participants; age ≥65 y.; Screening: CSID Conversion
from CIND
to dementia
16 · 1%; From
CIND to normal
25 · 3%
NA Sex
Dementia: DSM-III-R/ICD-10423 clinically assessed after
screening; 152 diagnosed
with CIND; 28 (men 7) with
dementia, 87 followed
up for 2 years.
Perkins [36],
2002
Ibadan-Nigeria
community
Prospective,
1992-1993
2487 participants; age ≥65 y; Screening: CSID NA 1.8% Dementia associated
with mortality
Dementia: DSM-III-R/ICD-10423clinically assessed
after screening
Indianapolis-USA,
Community
Prospective
Baseline survey
in 1992-1993
2212 participants;
aged ≥65 y.;
Screening: CSID 4.9% Dementia associated
mortality (adjusted
RR: 2 · 05)
342 clinically assessed
after screening
Dementia: DSM-III-R/ICD-10
Lane [37], 2003 Nigeria
Community
Prospective 8.7 y
follow up Baseline
1992-1993
968 participants
(271 aged ≥75 y.);
Screening: CSID NA NA ApoEε4 alleles not
associated with
increased mortality
23with dementia
at follow-up
Dementia: DSM-III-R/ICD-10
Indianapolis-USA,
Community
Prospective 9.5 y.
Baseline 1992-1993
353 participants (17 4 aged
≥75 y.); 17 with dementia
at follow-up
Screening: CSID NA NA ApoEε4 associated
with increased mortality
for patient under 75 yearDementia: DSM-III-R/ICD-10
Ogunniyi [45],
2005
Nigeria,
Community
Cross-sectional/
1992- 1998
98 demented subjects;
age ≥65 y.
Screening: CSID NA AD: 82% of all cases NA
Dementia: DSM-III-R/ICD-10 VaD: 11.1% of all cases
Kengne [16],
2006
Cameroon, Cross sectional, 4041 neurologic consultations Not provided NA 0.4% (all neurologic
admission), 19%
(neurodegenerative
diseases)
NA
Hospital 1993-2001 145 with neurodegenerative
diseases
16 (men 14) with dementia,
mean age 67.8 y.
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Gureje [46],
2006
Nigeria,
Community
Cross-sectional,
2003-2004
2152 participants at baseline
with a respondent rate of
74% (1904 participants).
Aged 65 year or older.
adapted 10-Word Delay
Recall Test (10-WDRT)10
NA Overall: 10.1%; Female gender,
Increasing age, alcohol
Female: 14.6%
Men: 7.0%
Gureje [71],
2006
Nigeria
Community
Cross-sectional, 2245 DNA samples,
830 had a diagnosis
Screening: CSID NA Any dementia (16.9% E4 allele in AD
(normal subjects)
26 · 0% (21 · 7%)Dementia: DSM-III-R/ICD-10 AD: 14.8%
Ogunniyi [72],
2006
Nigeria,
Community
Case–control 62 participants with AD
(Men 16.1%, mean age 82 y)
and 461 non demented
(men 33.2%, mean age 77 y)
Screening: CSID NA Age (OR 1 · 07)
Dementia: DSM-III-R/ICD-
10/AD: NINCDS-ADRDA
Rural to age (OR 2 · 93)
Hypertension (OR 0 · 33)
Indianapolis-USA,
Community
Case–control 89 participants with AD
(men 30.3%, mean age 83 y),
mean age 77 y) and 381 non
demented (Men 31.2%,
mean age 78 y)
Screening: CSID NA Age (OR 1.09
Rural to age (OR 2.08)
Dementia: DSM-III-R/ICD-
10/AD: NINCDS-ADRDA
Alcohol consumption
(OR 0.49)
Uwakwe [64],
2006
Nigeria,
Community
Cross-sectional 30 patients (men 12) with
dementia and their
caregivers (total 30)
Not provided NA N:52;
2003-2005 AD: not provided
Men: 12
Ochayi [47],
2006
Nigeria,
Community
Cross-sectional
2002
280 participants; age ≥65 y.; CSID NA Overall dementia: 6.4% Female gender,
Lower body mass
index, age, NSAIDS
65-74 year old: 5.2%
18 (men 2) with dementia ≥85 year 16%.
Hall [48], 2006 Nigeria,
Community
Cross-sectional 1075 participants; age ≥ 70 y.
29 (men 5) with AD,
NINCDS-ADRDA NA NA Total- or LDL-
cholesterol in
individuals without
the APOE-ε4 allele
Uwakwe [73],
2009
Nigeria,
community
Cross-sectional 914 (men 432) participants,
age ≥65 y; 87 with ≥2 tests
memory tests impaired
Memory impairment
assessed by MMS, CISD
and 10 word list immediate
and delayed recall
NA 9.9% NA
Guerchet [50],
2009
Benin Community Cross-sectional 502 (men 156) participants,
aged ≥65 y; 52 with
cognitive impairment
Screening: CSI-D NA Cognitive impairment Age, current depressive
disorder, absence
of the APOE ε 2Overall: 10.4%; men
7.7 women 11.5%
Dementia: DSM-IV
AD: NINCDS-ADRDA Dementia Overall:
2.5%, men 0.6%
women 3.4%
13 (men 1) with dementia
Toure [67], 2009 Senegal Cross-sectional 872 participants; age ≥55 y. DSM-IV-R NA Overall 6.6% Age, social isolation,
history of stroke,
epilepsy, family
history of dementia,
Parkinson’s disease
Hospital 2004-2005 58 cases of dementia
Burkina Fasso Cross-sectional DSM-IV NA NA
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Napon [68],
2009
15815 (2396) out (in) participants;
age ≥15 y.; 72 (and 53 inpatients)
with dementia; AD: 7; VaD: 19 cases
outpatients: 0.45%
inpatients: 0.22%
Hospital
Guerchet [49],
2010
Central African
Republic
Community
Cross-sectional 509 interviewed; 496 (men 218)
included in final sample, age ≥65 y.
Screening: CSID NA Overall: 8.1%, men 2.7%,
women 12.2%
NA
2008-2009 Dementia: DSM-IV
188 with cognitive impairment and
40 (men 6) with dementia (mean
age 76 y.); 33 (men 3) with AD
and 7 (men 2) with VaD
AD: NINCDS-ADRDA
Hachinski scale,
Republic of
Congo
Community
Cross-sectional 546 interviewed; 520 (men 198)
included in final sample,
age ≥65 y.148 with cognitive
impairment and 35 (men 9)
with dementia (mean age 79 y.);
24 (men 7) with AD and 11
(men 3) with VaD
CSID/ DSM-IV and
NINCDS-ADRDA
Hachinski scale
Overall: 6.7%, men 4.5%,
women 8.1%
NA
2008-2009
Chen [65], 2010 Kenya Cross-sectional 100 participants; age≥ 65 y. CSI-D using a version
in Kikuyu.
NA Apo ε4 allele frequency: NA
Hospital Demented 31.3%,
non-demented 32.2%
84 controls (men 38) and 16
with dementia participants
(men 7)
Ekenze [21],
2010
Nigeria Cross-sectional 8440 admissions; 1249 (men 640)
with neurological diseases
(age range18-83 y.); 38 (men 23)
with dementia
Not specified NA 3% NA
Hospital 2003-2007
Siddiqi [69],
2009
Zambia Cross-sectional 443 inpatients (men 219);
median age 39 y., 67 with
HIV; 368 outpatients (men 168);
median age 39 y., 58 with HIV;
36 with dementia
Not specified NA Dementia: Dementia in HIV +
patients 8 (13.8%) vs.
general population
9 (2.9%) (p = 0.002)
Overall: 4.4%Hospital 2006
Yusuf [74], 2011 Nigeria
Community
Cross-sectional 322 participants (men 128);
mean age: 75.5 y
Screening:
CSID/CERAD/SDT
NA Dementia: 2.8% Age
AD: 1.9%
VaD: 0.6%Dementia: DSM-IV
and ICD-10
9 cases of dementia (men 3);
mean age: 82.4 y
LBD: McKhan clinical
criteria
FTD: McKeith clinical
criteria
Gureje [51],
2011
Nigeria,
Community
Prospective Cohort
Baseline 2003-2004
2,149 participants at baseline 10-Word Delayed Recall 21.80/1,000 NA Poor social engagement,
rural residence, low
economic status, female
gender, age.
Test (cut off of 18)1,408 at 39 months follow-up; 85
(among ≥65 y.) developed dementia
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Ogunniyi [52],
2011
Nigeria
Community
Cohort study 1559 participants aged > 65 year
without dementia a baseline. 136
(men 33) with dementia (mean
age 83.1 y.) at follow-up; 255
with MCI
Dementia: DSM-III-R
and ICD-10
Dementia:
8.72/1,000/year
NA Low BMI
1992-2007 MCI: 16.35/
1000/year
Ogunniy [53],
2011
Nigeria
Community
prospective cohort
baseline 1992
2718 participants interviewed Dementia: DSM-III-R
and ICD-10
Dementia/AD/VaD
(per 1,000/year)
11.50/9.50/1.10
NA Higher SBP, DBP and PP
1753 (age ≥65 y.) in the final sample
120 (men 30) with dementia
(mean age 83.8 y.); 99 with AD;
11 with VaD
Paraïso [56], Benin Community Cross-sectional 1,139 (men 523) participants;
age ≥65 y.; 42 (men 13) with
dementia (mean age 79 · 1 y)
Screening: CSI-D NA Dementia Overall 3.7%
men 1.1% women: 2.5%
NA
2011 2008 Dementia: DSM-IV
32 with AD, 105 with CIND AD: NINCDS-ADRDA AD Overall 2.8%
VD Overall 0.8%VaD: NINCDS-AIREN
Amoo [30], Nigeria Cross-sectional 240,294 participants Dementia: ICD-10 NA Dementia: 45/100,000 NA
2011 AD; 25 · 8/100,000
Hospital 1998-2007 VaD: 7 · 4/100,000108 (men 51) with dementia
(mean age: 70.1); 62 (men 24)
with AD; 18 (men 13) with VaD;
4 (men 2) with mixed forms;
ADNINCDS – ADRDA
VaD: NINCDS –AIRENS
LBD: McKeith criteria,
FTD: Lund and
Manchester Criteria
4 (men 2) with FTD; 3 (men 0)
with DLB; 13 (men 2) with
unclassified dementia
Ndiaye [31],
2011
Senegal Cross-sectional 132 patients seen at a memory
clinic (men 41, mean age: 67 y
Screening: “Test du
Senegal”/modified
HodKinson test
NA MCI: 14.4% NA
Hospital 2004-2005
57 with dementia; 37 with AD,
10 with VaD, 5 with FTD and
1 with LBD.
Dementia: 43.2%
AD: 64.7% of all cases
of dementia
MCI: Petersen criteria
Dementia: DSM-IV
Coume [75],
2012
Senegal Cross-sectional 872 (men 546) participants
aged >55 y; mean age 67 · 2 y
Test du Senegal NA Cognitive
impairment 10.8%
NA
Hospital 2004-2005 94 (men 65) with cognitive
impairment (74 aged > =65 y)
Baiyewu [54].,
2012
Nigeria Cross-sectional/
2001 and 2004
21 (men 4) participants with
normal cognition (mean
age 82.8 y.)
Screening: CSID NA NA NA
Dementia:
DSM-III-R/ICD-10
Community 53 (men 4) with cognitive
impairment (mean age 80.9);
34 (men 6) with dementia
(mean age 83.3 y)
AD: NINCDS-ADRDA
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Table 2 Overview of studies on dementia and risk factors in sub-Saharan Africa (Continued)
Toure [66], 2012 Senegal Cross-sectional 507 participants; age ≥65 y. Screening: Aging in
Senegal Questionnaire
NA 8.9% advanced age
(Age ≥80 y, OR 4.3,
95% CI 1.4-13), illiteracy,
epilepsy, family
history of dementia
45 with dementia DSM-IV-RHospital 2004-2005
Longdon [57],
2012
Tanzania Cross-sectional 1198 (men 525) participants;
age ≥70 y; 78 with dementia
Screening: CSI-D NA 6.4% Advanced age
Community 2010 DSM-IV-R
Onwuekwe [76],
2012
Nigeria Cross-sectional 135 participants (men: 79),
aged between 16–76 y
MMSE (cut off of
17 for MCI)
NA MCI: 5.9%
Hospital 2004
8 with MCI
Guerchet [55],
2012
Central African
Republic, Congo
Cross-sectional 509 interviewed; 496 (men 218)
included in final sample; age
≥65 y.; 188 with cognitive
impairment
Dementia: DSM-IV-R/AD:
NINCDS-ADRDA
NA Dementia: 7.4% Hypertension, low BMI,
depressive symptoms,
change of residence,
age (OR 2.59, 95% CI,
early death of one
parent, female gender
2008-2009
Community AD: 5.6%
546 interviewed; 520 (men 198)
included in final sample; age
≥65 y.; 148 with cognitive
impairment
Overall 75 (men 15) had dementia
18 with vascular dementia
AD: Alzheimer’s disease; APOE: Apolipoprotein E; ICD: International Classification of Disease; BMI: Body Mass Index; CI: confidence Interval; CIND: Cognitive Impairment and No Dementia; CSID: Community Screening
Interview for Dementia; DSM-III-R: Diagnostic and Statistical Manual 3rd edition revised; MMSE: Mini Mental State Examination; NA: Not available; NFT: Neurofibrillary tangle; NINCDS/ADRDA: National Institute of
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; OR: Odd ratio; SCEB: short cognitive evaluation battery; USA: United States of America; VaD:
Vascular dementia; y: years.
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http://www.biomedcentral.com/1471-2458/14/653[30-32,34,42,45,55,56,63,71,74], followed by vascular de-
mentia 5.7 to 31.0% of cases [30,31,45,56,74]. Four publi-
cations in Nigeria provided incidence data for dementia
ranging from 8.7 to 21.8 cases per 1000 per year
[35,51-53]. Incidence of Alzheimer disease ranged from
9.5 to 11.5 per 1000 per year [35,53].
The most commonly used tool for dementia screening
was the Community Screening Interview for Dementia
(CSID) questionnaire applied in 20 publications [32,34,36,
37,41-43,45-47,49,50,54,56,65,70]. The diagnosis of de-
mentia mainly relied on the DSM-III-R/DSM-IV and
ICD-10 classification [30,32,34-37,40,42-46,52-54,63,70].
The diagnosis of Alzheimer’s disease was based on the Na-
tional Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS/ADRDA) criteria
[30,32,34,35,41,43,48,50,52-56,75]. Population-based stud-
ies that used DSM-III/DSM-IV and ICD-10 for dementia
reported prevalences ranging from 1.1 to 8.1% [32,35,42,
49,55-57,65,67,74] (ref 13, 16, 23, 30, 36–38, 48, 50, 118).
Likewise the prevalence of Alzheimer’s disease ranged
from 0.7 to 5.6% based on NINCDS/ADRDA criteria
[35,42,55].
Risk factors for dementia were reported in 14 publica-
tions. The following were associated with an increased risk
of dementia: age (twelve publications), female sex (five
publications), low body mass index (three publications),
anxiety/depression (three publications), hypertension
(three publications), social isolation (two publications),
lifetime history of alcohol consumption, elevated total- or
LDL cholesterol in those without Apo E ε4 (one publica-
tion), low socio-economic status, history of stroke and
family history of dementia (one publication). The follow-
ing characteristics were inversely associated with de-
mentia: living with others, use of non-steroidal anti-
inflammatory drugs and absence of Apo E ε2. Some risk
factors were more strongly related to the disease. These
include age, which increased the risk of dementia by five
to 16% across groups [34,43], but this effect was much
higher after the age of 60 years, more than 100% increase
risk especially after the age of 75 [46,50,51,55,66,67].
Female sex, low level of education (<6 years), rural resi-
dence and family history increased the risk of dementia
by >100% [34,43,46,55,56,66].
HIV-related neurocognitive impairment
Fifty-one hospital-based studies (47 publications) reported
on HIV-related neurocognitive impairment (Table 3), of
which ten were case–control, six cohort and 31 cross-
sectional. These studies were conducted in 14 countries
including South Africa (14 studies), Uganda (eight stud-
ies), Nigeria (six studies), Zambia and Kenya (four studies
each), Cameroon and Democratic republic of Congo
(three studies each) Ethiopia and Malawi (two studieseach), Central African Republic, Botswana, Guinea Bissau,
Tanzania and Zimbabwe (one study each). A total of 33
out of the 47 selected publications were published during
the last 5 years and only 7 before 2000. The absolute num-
ber of participants with HIV-related dementia ranged
from 0 to 396, with a prevalence ranging from 0% to 80%.
The diagnostic tools used to identify HIV-related de-
mentia were variable, making comparison between studies
less reliable. However, the International HIV Dementia
Scale (IHDS) [89,95,97,105,107-110,112,113,120,121] and
the Sloan Memorial Kettering scale [86,89,90,98] were fre-
quently used. Studies that used the IHDS reported a
prevalence ranging from 21.1 to 80%. The mean/median
age of participants ranged from 31 to 40 years for those
with HIV-related dementia, and men represented 25% to
56% of this group. In the nine studies that investigated
etiological factors, the identified determinants of HIV-
related dementia were: low level of CD4 count (four stud-
ies), low level of education, and advanced age (three
studies), comorbid psychiatric conditions (two studies
each), advance clinical stage (two studies), male sex, HIV-
subtype and duration of disease (one study each). The
most commonly reported risk factors of HIV associated
dementia were the level of CD4 count [89,97,112,120,121]
and the clinical stage of disease [97,121].
Amyotrophic lateral sclerosis and cerebellar degeneration
Fifteen studies (12 retrospective, 2 cross-sectional and 1
case-series) (Table 4) including 13 hospital and two
community-based studies on amyotrophic lateral scler-
osis (ALS) have been conducted in 9 SSA countries in-
cluding Nigeria (four studies), Senegal (three studies),
Ethiopia (2 studies), Zimbabwe, Kenya, South Africa,
Sudan, Cameroon and Ivory coast (one study each). The
number of participants with ALS ranged from two to 73.
Two community-based studies provided a prevalence of
15/100,000 and 5/100,000 respectively in Nigeria [19]
and in Ethiopia [122]. Five hospital-based studies pro-
vided prevalence figures: between 0.2 and 8.0/1000 of all
neurologic consultation/admission [16,21,122-126]. The
method of ascertainment of ALS was variable across
studies, but electromyography was done in four of the
fifteen studies included [125-129]. The proportion of
men among those with ALS was 57.6 to 100%. The age
of those with ALS ranged from 12 to 84 years. When
provided, the age at the clinical onset of ALS ranged
from 12 to 71 years and the time to diagnosis from
3 months to more than 15 years. In general, risk factors
for ALS were not investigated across studies.
One retrospective study in Nigeria reported on two
cases (a 32 year old male and a 42 year old female) of
cerebellar degeneration among 2 · 1 million admissions
over a period of 25 year [14]. One study in Rwanda re-
ported on a family of 33 members, with 15 (including
Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan
Author, year
of publication
Country/setting Design/study
period
Population characteristics Diagnostic criteria Prevalence Risk factors Comments
Belec [77],
1989
Central African
republic,
Hospital
Cross-sectional
1987
93 HIV + participants; age and
sex not specified
Not reported HAND: 3 cases (3.2%) NA No neuro-imaging or
neuropathological
studies
Howlet [78],
1989
Tanzania,
hospital
Cross-sectional
1985-1988
200 (men 129) HIV +
participants; mean age: 32 y
Decline of memory and
other functions
Dementia complex:
54%
NA
Turnbull [79],
1991
South Africa Cross-sectional
1982-1983
27 haemophilic patients
with HIV infection
Battery of neuropsychological
tests: Rey complex figure,
Babcock story, digit span,
WAIS
HAND: 4 cases
(14.8%)
NA
Perriëns [80],
1992
Democratic
republic of
Congo
Hospital
Cross sectional
2008
104 (men 48) HIV +
participants; mean age:
34.3 y.; 92 (men 53) HIV-
participants; mean age 44 y
9 (men 5) HIV + with HAND
WHO operational criteria/
American Academy of
neurology criteria
HIV Associated
|Dementia Complex.
8.7%
NA No neuro-imaging study
Maj [81], 1994 Kenya
Hospital
Cross sectional
1990-1991
65 (men 49) HIV- participants;
mean age: 30 y.; 66 (men 42)
asymptomatic HIV + participants;
mean age 30.7; 72 (men 48)
symptomatic HIV + participants;
mean age: 33.2 y
ICD-10/DSM-IV Dementia
HIV- 0
Asymptomatic
HIV + 0
Symptomatic
HIV + 6 (%)
NA
Democratic
republic of
Congo
Hospital
85 ( men 48) HIV- participants;
mean age: 33.9 y; 52 (men 33)
asymptomatic HIV + participants;
mean age 32.3 y.; 68 (men 35)
symptomatic HIV + participants;
mean age: 33.8 y
ICD-10/DSM-IV Dementia
HIV- 0
Asymptomatic
HIV + 0
Symptomatic
HIV + (5.9%)
NA
Carson [82],
1998
Kenya Cross sectional 78 (men 52) HIV + participants;
mean age: 29.9 y.; 138 (men 114)
HIV- participants; mean age 29.8 y.
Revised WAIS, Trails A and
Trails B tests, Digit span,
Delayed word and d
recognition
NA NA No difference in
neuropsychiatric test
performance between
HIV + and HIV-
Hospital 1994
Sebit [83],
1995
Kenya Cross sectional 191 participants, 72 (men 48)
symptomatic HIV + (mean
age 33.2 y.), 66 (men 42)
asymptomatic HIV +
(mean age 30.7) and 65
(men 49) HIV- (mean age 30 y.)
WHO operational criteria/
American Academy of
neurology criteria
Mental disorders: NA No specific data for HIV
associated neurocognitive
disordersHospital 1990-1991 Symptomatic
HIV + 7.1%,
Asymptomatic HIV +
4.5%, HIV −0
Democratic
republic of
Congo (DRC)/
Hospital
190 participants, 68 (men 35)
symptomatic HIV + (mean
age 33.8 y.), 52 (men 33)
asymptomatic HIV + (mean
age 32.3) and 85 (men 48)
HIV- (mean age: 33.9 y.)
WHO operational criteria/
American Academy of
neurology criteria
Mental disorders: NA No specific data for HIV
associated neurocognitive
disorderssymptomatic HIV +
5.9%, asymptomatic
HIV + 1.9%, HIV– 1.2%
Lekoubou
et
al.BM
C
Public
H
ealth
2014,14:653
Page
16
of
32
http://w
w
w
.biom
edcentral.com
/1471-2458/14/653
Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan (Continued)
Sacktor [84],
2006
Uganda,
Hospital
Prospective 23 (men 5) HIV + participants on MSK HIV dementia
scale IHDS
Baseline: Subclinical
dementia 35%
NA All participants had CD4
count ≤200 cells/mL and
an IHDS ≤ 10 (suggestive
of HAND)
Cohort study
2004-2005 HAART (mean age 32.8 y.)
Re-assessment at 3 and 6 months. Mild dementia 61%
At 3 (6) months: mild
dementia 26% (4%)
Sacktor [85],
2005
Uganda,
Hospital
Cross-sectional
2003-2004
81 HIV+; mean age: 37 y.;
100 HIV- mean age: 31.4 y;
21 had HIV dementia
IHDS (cut off ≤10), HIV dementia: 31% NA
MSK HIV dementia scale
Modi [86],
2007
South-Africa,
Hospital
Cross-sectional 506 HIV + (men 203) on HAART;
mean age/range: 37 years 193
had HIV associated dementia
American Academy of
Neurology AIDS Task force
HIV dementia: 38% NA 75% had CD4 below
100 cells/mm3
2005
Clifford [87],
2007
Ethiopia,
Hospital
Case–control 73 (men 67%) HIV + participants
(median age 39 y.);
IHDS NA NA Quantitative
neuropsychiatric
tests - no difference
between groups
2004
87 (men 63%) HIV- participants
(median age 38 y.)
Odiase [88],
2007
Nigeria,
Hospital
case–control 96 (men 48) symptomatic HIV +
patients (mean age 33.6 y.),
FePsy computerized
neuropsychological
test battery
NA NA Severity of immune
suppression predictive
of cognitive decline2004
96 (men 48) asymptomatic HIV +
(mean age 31.5 y.); 96 (men 48)
HIV- (mean age 32.9 y.)
Wong [89],
2007
Uganda,
Hospital
Cross-sectional 78 (men 28) HIV + participants
(mean age 37 y.); 24 (men 6)
with dementia; 100 HIV –
participants
MSK HIV dementia scale HIV dementia. 31% Age, low CD4
count associated
HIV dementia2003-2004
Robertson [90],
2007
Uganda,
Hospital
Cross-sectional 110 (men 34) HIV + participants
(WHO Stage 2/3/4, n = 21/69/20);
mean age 36.7 y.; 49 on HAART
MSK HIV dementia scale NA NA Pattern of
neuropsychological
deficits similar to that in
western countries.
2003-2004
100 (men 60) HIV– controls
(mean age 27.5 y.)
Salawu [91],
2008
Nigeria,
hospital
Cross-sectional 60 HIV + (men 24), asymptomatic,
naïve of HAART; mean age 32 y)
CSID 56.7% No correlation
between CD4
count and
performance on
neuropsychological
testing
60 HIV- (men 24); mean age: 30.1 y;
34 had HIV dementia
Singh [92],
2008
South Africa,
Hospital
Cross-sectional 20 HIV + (men 8) participants;
median age 34 y
IHDS-criteria (cut-off ≤10) HAND: 80% NA CD4 < 200 cells/mm3,
older than 18 years and
not be delirious.
2007 16 had HAND
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Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan (Continued)
Säll [93], 2009 South Africa,
Hospital
Retrospective 38 HIV + admitted to the
psychiatric ward with psychiatric
symptoms; mmean age 32.4 y
DSM-IV Dementia: 32% NA
1987-1997
12 had dementia
Ganasen [94],
2008
South Africa,
Hospital
Cross-sectional 474 (men 123) HIV + patients
(328 blacks and 135 coloured);
mean age 34 y.
HIV dementia scale HAND: 17.1% (IHDS)
and 2.3% (MMSE)
NA
MMSE
Njamnshi [95],
2008
Cameroon,
Hospital
Case–control
study 2006
204 (men 64) HIV + participants
(mean age 37.2 y.); 204 (men 64)
HIV- participants (mean age 37.1 y.)
IHDS-criteria (cut-off ≤10) HAND: NA
HIV+: 21.1%
HIV-: 2.5%
Sacktor [96],
2009
Uganda,
Hospital
Prospective
cohort
102 (men 29) HIV + never
treated patients (mean age
34.2 y.) started on Stavudine-
based HAART
IHDS criteria Base line: 40% had
HIV dementia (33%
mild, 7% moderate)
NA
MSK HIV dementia scale
2005-2007
Follow-up
6 months
25 (men 15) HIV-
(mean age 30.3 y.)
At 3 months: 26%,
23% mild, 3%
moderate
At 6 months: 16%
(13% mild, 3%
moderate
Njamnshi [97],
2009
Cameroon,
Hospital
Cross-sectional 185 (men 61) HIV + participants
(mean age 37 y.); 41 with
possible HAND (mean age 37y.)
IHDS-criteria HAND: 22. 2% Advanced clinical
stage, low CD4
count, and low
haemoglobin
levels
2006
Sacktor [98],
2009
Uganda, Cross-sectional 60 HIV + never treated
participants; 22 with
dementia
IHDS criteria Overall: 36.7% HIV subtype D
associated with
increased risk of
HIV dementia
All participants had CD4,
count ≤200 cells/mL
and an IHDS ≤ 10
(suggestive of HAND)
Hospital 2005-2007 MSK HIV dementia scale
Nakasujja [99],
2010
Uganda, Prospective
cohort
102 HIV + (men 28); mean
age: 34.2 y; 70 with cognitive
impairment at baseline
IHDS (cut-off ≤10) Base line: 68.6% NA
Hospital
2005-2007 neuropsychological
tests and MSK HIV
dementia scale
At 3 months: 36%
At 6 months: 30%
Kinyanda [100],
2011
Uganda, Cross-sectional 618 HIV + (men 169), 83% <45 y IHDS (cut-off ≤ 10) 64%
396 had cognitive disordersHospital 2010
Choi [101],
2011
Guinea Bissau, Case–control 22 HIV-2 + (men 4)participants
mean age for those with CD4
< 350 = 55.1 y, mean age for
those with CD4 ≥ 350 = 50.3 y)
IHDS HIV+: 22.7%
(CD4 < 350 = 27%,
CD4 ≥ 350 = 18%)
age (β = −0.11)
Hospital
45 HIV- controls (men 1); mean
age51 · 9 y)
MSK HIV dementia scale Control: 11%
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Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan (Continued)
Birbeck [102],
2011
Zambia,, Cross-sectional 496 HIV + (men 205) participants
screened within 1 week of
initiating ART; mean age 38.1 y)
I\HDS (cutt-off ≤ 10) 42.1% (IHDS) NA Low IHDS score was
associated with poor
adherence to HAARTHospital 2006-2007 MMSE (<=22) 34.4% (zMMSE)
IHDS administered to 440
participants.
185 had dementia
Joska [103],
2010
South Africa,
Hospital
Cross-sectional 536 (men 26.7%) HIV +
participants (68% blacks,
28% coloured), mean age 34 y.
HDS (cutt-off ≤ 10) HAND: 23.5% Age, education,
diagnosed duration,
post-traumatic
stress disorder
IDHS not yet available by
the time of the study
Kanmogne
[104], 2010
Cameroon Case–control 43 (men 18) HIV- participants
(mean age 33.3 y.); 44 (men 17)
HIV + participants (mean age
34.9 y.); 22 with AIDs defining
conditions, 34% on HAART
HIV Neurobehavioral
Research Center
International
neuropsychological
test battery
NA NA
Hospital 2008-2009
Lawler [105],
2010
Botswana, Cross-sectional 120 (men 60) HIV + patients
(mean age 37.5 y.); 97.5%
on HAART;
IHDS-criteria (cut-off ≤9.5) HAND: 38% NA
2008 46 with HIV dementiaHospital
Patel [106],
2010
Malawi,
Hospital
Cross sectional 179 (men 63) HIV + participants
(mean age 36.7 y.); Stage III/IV
90%; 134 on HAART > 6 months;
IHDS-criteria (cut-off ≤10) HAD Female gender,
low education
2007
25 (men 14) with HIV dementia Overall: 14%
Men: 22.2%
Women: 9.5%
Siddiqi [69],
2009
Zambia Cross-sectional 443 (men 219) inpatients
(median age 39 y., 67 HIV+);
368 (men 168) outpatients
(median age 39 y., 58 HIV+);
Overall 36 cases of dementia
Not specified NA HIV+: 10.4% HIV + patient had a
higher frequency of
dementia and had
dementia at
younger age
Hospital HIV-: 3.3%
Ekenze [21],
2010
Nigeria,
Hospital
Cross-sectional 8440 admissions; 1249
(men 640) with neurological
diseases (mean age 45 y.);
44 (men 18) with AIDS
dementia complex
Not specified AIDS dementia
complex: 3.5% of
all neurological
admission
NA
2003-2007
Holguin [107],
2011
Zambia,
Hospital
Case–control 57 (men 30) HIV- participants
(mean age 28 y.); 83 (men 32)
HIV + (mean age 34 y.)
including 54 naïve of HAART
IHDS (cut-off ≤ 10) HAND = 22%
among HIV +
naïve of ARV
NA
Color Trails Test 1 and
2008 2, Grooved pegboard Test,
and Time Gait Test
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Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan (Continued)
Joska [108],
2011
South Africa,
Hospital
Case–control 94 (men 36) HIV- participants
(mean age 25.2 y); 96 (men 20)
HIV + (mean age 29.8 y)
IHDS NA Education associated
with IHDS total score
Validation study of
the IHDS
2008
Obiabo [109],
2011
Nigeria, Prospective
Cohort study
69 (men 25) HIV + participants
with CD4 < 350 (mean age
36.2 y.); 30 (men 11) HIV-
(mean age 36.6 y.)
CSID and FePsy
computerized
neuropsychological
test battery
NA NA HAART improved
neuropsychological
performances after
12 months of treatment
Hospital
Joska [110],
2011
South Africa
Hospital
Cross-sectional 170 (men 44) HIV + participants
(mean age 29.5 y.)never treated;
43 (men 14) with HIV-dementia;
72 (men 19 with MND
AAN revised criteria Mild neurocognitive
disorder: 42.4% HIV
dementia: 25.4%
Education, and male
gender independent
predictors of
HIV-dementia
2008-2009
Robertson
[111], 2011
Malawi, Cross sectional 133 (men 39) never treated
HIV + patients (median
age 31 y.)
Not provided MND: 8%
HAD: 0%Hospital
South Africa, 167 (men 60) never treated
HIV + patients (median
age 34 y.)
Not provided MND: 4%
HAD: 0%Hospital
Zimbabwe,
Hospital
80 (men 31) never treated
HIV + patients (median
age 36 y.)
Not provided MND: 14% NA 860 HIV + HAART naïve
patients with CD4 count
< 300 cells/mL and KI ≥70%HAD: 3%
Robbins [112],
2011
South Africa, Cross-sectional 65 (men 23) HIV + patients
on HAART for ≥6 months
(mean age 38.5 y)
IHDS and Xhosa-validated
IHDS
HIV Associated
dementia 80%
Low CD4
counts, alcohol
dependencyHospital 2009-2010
Kwasa [113],
2012
Kenya, Cross sectional 30 (men 17) HIV + patients
(mean age 39 y.)
Neuropsychological test
battery MMSE/IHDS
(cut-off ≤10)
HAD 20% NA
Hospital 6 (men 5)with HAD
Spies [114],
2012
South-Africa, Case–control 35 HIV + without childhood
trauma; mean age: 31.5 y
Neuropsychological
test battery
NA NA Significant HIV effects for
the Hopkins Verbal
Learning Test (HVLT)
learning and delay trials
and the Halstead
Category Test (HCT)
Hospital 48 HIV + with childhood
trauma; mean age: 31.7 y
27 HIV- without childhood
trauma; mean: 25y
20 HIV- with childhood
trauma; mean age: 27 · 7 y
All participants were women.
Hestad [115],
2012
Zambia,
Hospital
Case–control 38 HIV + (men 16); mean
age: 28.3 y 42 HIV- (men 18);
mean age: 28.9 y
Neuropsychological tests NA NA HIV + individuals
performance lower than
that of HIV- on verbal
fluency, executive
function, speed of
information processing,
verbal episodic memory
and motor function
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Table 3 Overview of studies on HIV-related dementia and risk factors in sub-Saharan (Continued)
Berhe [116],
2012
Ethiopia, Cross-sectional 347 HIV + (men 176) participants;
mean age/range: 34.6 y admitted
with neurological disorders
“cognitive and motor
abnormalities, CT/MRI
showing brain atrophy
and other opportunistic
infections ruled out”
HIV encephalopathy:
0.3%
NA
Hospital Retrospective
10 had dementia2002-2009
Joska [117],
2012
South Africa, Prospective 166 HIV + participants assessed
at baseline, 108 reassessed at
one year (82 received HAART)
Neuropsychological tests NA Lower level of
education
Improvement on
neuropsychological
tests for all participants
at one year.
Average Global
deficit score
Hospital
Breuer [118],
2012
South Africa, Cross-sectional 269 HIV + (men 97) participants
on HAART for ≥6; months; 34%
aged >40 y)
IHDS (cut-off ≤10.5) HAND: 12% NA
Hospital
Hoare [119],
2012
South Africa Cross-sectional 43 stage III HIV + (24 with at least
one ε4 ApoE allele, men: 8, Age:
29 y and 19 without the ε4 ApoE
allele, men: 2, Age: 28 y)
Neuropsychological
test battery
NA Performance on
Hodgkin Verbal
Learning Tool-
Revised was poorer
in the group with
the ε4 genotype.
Participants with
the ε4 genotype
had more white
matter injury
on MRI.
Hospital
Oshinaike
[120], 2012
Nigeria Case–control 208 HIV + (men 71),
mean age: 36.8 y
IHDS (cut off ≤10) HAND by MMSE: 2.9% Lower CD4 count
Hospital 2007-2008
121 HIV – (men: 35),
mean age:38.0 y
MMSE (cut off ≤26)
AAN revised criteria
(any value below 2SD)
HAND by IHDS: 54.3%
HAND by AAN: 42.3%
Royal [121],
2012
Nigeria,
Hospital
Cross-sectional 60 (men 23) never
treated HIV + participants
(mean age 34 y);
IHDS (cut off ≤10) 28.8% HIV + individuals
scored abnormally
Low CD4 count,
WHO clinical stage
of disease
56 (men 34) HIV-
(mean age 29 · 4 y.);
32 had dementia
16.0% HIV- individuals
scored abnormally
3TC: Lamivudine; AIDS: Acquired Immunodeficiency Syndrome; CD4: cluster of differentiation 4; CSID: Community Screening Interview for Dementia; CT: computerized tomography; DSM-III-R: Diagnostic and Statistical
Manual 3rd edition revised; DSM-IV: Diagnostic and Statistical Manual 4th edition; dT4: Didanosine; FePsy: The Ion Psyche Program; HAART: Highly Active Anti-Retroviral Treatment; HAD: HIV Associated Dementia; HAND:
HIV Associated Neurocognitive Disorders; HDS: HIV Dementia Scale; HIV: Human Immunodeficiency Virus; ICD-III-R: International Classification of Disease; IHDS: International HIV Dementia Scale; MSK: Memorial Sloan
Kettering; MMSE: Mini Mental State Examination; MND: Mild Neurocognitive Disorder; NA: Not available; NVP: Nevirapine; WHO: World Health Organization; y, years; ZDV: Zidovudine.
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Table 4 Overview of studies on amyotrophic lateral sclerosis risk factors in sub-Sahara Africa
Author, year
of publication
Country/setting Design/year Population characteristics Diagnostic criteria/tools Prevalence Risk factors Comments
Wall [130],1972 Zimbabwe Retrospective 13 (men 10) consecutive
patients; age 24–55 y.
Clinical (no ENMG) NA NA 6 participants had sensory
changes
Hospital-based 1967-1971
Osuntokun [126],
1974
Nigeria Retrospective 92 patients with MND ALS 73;
PMA 10, SMA 9
ENMG/Muscle biopsy/ 21/100,000 NA Mean age at onset: 39 y
Mean duration of disease
exceeded 15 y in 8% of
participants
Hospital-based 1958 -1973
4 patients with ALS had
poliomyelitis in childhood.
Osuntokun [19],
1987
Nigeria Cross-sectional 18954 participants (men 9282);
58% <20 y and 11% > 50 y
Screening questionnaire
developed by the authors
MND: 15/100,000 NA
Community-based 1985
Cosnett [125], 1989 South Africa
Hospital-based
Retrospective
Cases collected
during 9.5 y.
59 blacks (mean age 47.4 y.);
16 whites and 2 coloured
(mean age 54 y.) 9 Indians
(mean age 54 y)
Clinical and ENMG in 45% Blacks/white &
coloured/Indians
(per 100,000)
0.88/2 · 7/1.4
NA Mean age of onset: 47 y
(blacks) and 54 y (in whites
and Indians)
29% of participants not
followed up.
Ekenze [21], 2010 Nigeria Retrospective 8440 admissions; 1249
(men 640) with neurological
diseases, mean age 45 y.; 10
(men 4) with ALS
Not specified 800/100,000 NA
Hospital-based 2003-2007
Abdulla [127], 1997 Sudan Retrospective: 28 (men 17) patients with
MND; 19 (men 14) with ALS
Clinical and ENMG NA Family history
of MND in 14%
Mean age of onset: 40 y
Hospital-based 1993-1995
Kengne [16], 2006 Cameroon Retrospective 4041 neurologic consultations;
145 with neurodegenerative
diseases 10 (men 8) with ALS;
mean age 50.9 y.
Not provided 12% of all
neurodegeneration
250/100,000 of all
neurologic
consultation
4 selected degenerative brain
diseases: Dementia, PD, ALS
and choreaHospital-based 1993-2001
Imam [131], 2004 Nigeria Retrospective 16 (men 15) participants;
age 16-60 y.
El Escorial diagnostic
criteria for ALS, no ENMG
NA NA
Hospital-based 1980-99
Adam [129], 1992 Kenya Retrospective 47(men 35) participants
with MND;
Clinical (ENMG in 1/3
of participants)
NA NA Duration of disease: 5 m to 4 y.
Hospital-based 1978-88 Age 13-80 y
18 had ALS
Tekle-Haimanot [122],
1990
Ethiopia Cross-sectional 60820 participants (men 29412),
59% aged < 20 y
Screening questionnaire
and neurological exam
5/100,000 NA A population survey of
neurological diseases
Community-based 1986-88 3 (2 men) had MND
Harries [132], 1955 Ethiopia Case series 2(all males) participants Clinical (no ENMG) NA NA
Age 26 and 30 yHospital-based 1954
Lekoubou
et
al.BM
C
Public
H
ealth
2014,14:653
Page
22
of
32
http://w
w
w
.biom
edcentral.com
/1471-2458/14/653
Table 4 Overview of studies on amyotrophic lateral sclerosis risk factors in sub-Sahara Africa (Continued)
Jacquin-cotton [123],
1970
Senegal Retrospective 6100 participants with
neurological disorders
Clinical (No ENMG) 290/100,000 A study of patients with
paraplegia in a neurological
unit
Hospital-based 1960-1969 18 (16 men) participants
with ALS, age 25-70 y
Piquemal [124], 1982 Ivory coast Retrospective 4000 participants with
neurological disorders
Clinical (no ENMG) 750/100,000 NA Duration of disease: 3 m to 5 y.
Hospital-based 1971-80 30 (men 22) participants
had ALS, 50% aged <40 y
Collomb [133], 1968 Senegal Retrospective 18 (17 men) participants
with ALS, age 25-70 y
Clinical (no ENMG) NA NA Duration of disease: 4 m to 13 y
Hospital-based 1960-68
Sene [128], 2004 Senegal Hospital- Retrospective 33 (19 men) participants
with ALS;
El Escorial Definite ALS: 57%,
Probable: 30%, Possible ALS: 9%
Suspect ALS: 3% age at
onset 14–67 y.
(ENMG in half of the patients)
based 1999-2000 Duration of disease: 6 m to 5 y.
ALS: amyotrophic lateral sclerosis; ENMG: Electroneuromyography; MND: Motor Neuron Disease; NA: Not available; PMA: Progressive muscular atrophy; SMA: Spinal Muscular Atrophy; y: years; m: months.
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spino-cerebellar ataxia [134]. A study in Mauritania re-
ported on 12 cases of cerebellar degeneration-based on
clinical criteria, including 9 familial cases (including 7
men, aged 3 to 29 years) and 3 apparently sporadic cases
(all men, aged 8 to 50 years) [135]. Another clinic-based
study of paraplegia in Senegal reported on 7 cases of
spino-cerebellar degeneration among 6100 neurological
admissions [123].
Huntington disease
Nineteen studies (four community-based studies and 15
hospital-based) investigated Huntington disease; includ-
ing 8 cross-sectional studies (including reviews of med-
ical records), 10 case series (two to 13 patients), and one
case report (Table 5). The studies were conducted in
nine countries: South Africa (nine studies), Zimbabwe
and Tanzania (two studies each), Nigeria, Mauritius
Island, Senegal, Sudan, Togo and Burkina Faso (one
study each). The diagnostic of Huntington disease was
mostly clinical, based on a constellation of probing clin-
ical elements; however genetic testing was carried out
in five studies [136-140]. The absolute number of
participants with Huntington disease ranged from one
to 481. Only one community-based study provided
a prevalence estimate of 3.5/100,000 in South-Africa
[141]. The hospital-based prevalence of Huntington dis-
ease when reported ranged from 0.2/100,000 to 46.0/
100,000 [138,142-146]. No study reported data on the
incidence of Huntington disease. Among those with the
disease, males represented 42 to 100%, and age varied
from <9 years to 80 years. When provided, the age at
the clinical onset of the disease ranged from less than
one year to 58 years. In general, antecedent risk factors
for Huntington disease were not investigated across
studies except for a positive family history reported in
58.3 to 100% of cases.
Discussion
This review represents an unprecedented effort to sum-
marize epidemiological data on neurodegenerative dis-
eases in SSA. However, this being a large diverse
multicultural and multiethnic region, it is difficult to re-
liably quantify and compare the burden of neurodegen-
erative disorders across countries. Although mostly
based on prevalent cases and on retrospective data, from
studies that have essentially included urban populations,
findings summarized in the current review are very
informative.
The most widely investigated and prevalent neurode-
generative condition appeared to be dementia with most
cases being of Alzheimer disease type. Major risk factors
of AD include an advanced age (higher after the age of
60), female sex, a low schooling (less than 6 year ofeducation), family background and rural residence. Un-
like North America, Australia, Europe, and Japan where
several population-based studies have been conducted
on dementia, good quality epidemiological studies (pro-
spective, population-based, using standardized criteria)
are scanty in SSA, with methodological issues hampering
any meaningful comparison with other regions of the
world. The reported prevalence in one collaborative
good quality study in Nigeria about 20 years ago among
those aged >60 years was 2.3%. This was lower than the
reported prevalence in developing countries, but within
the range of reports from developing countries in Asia
and Latin America where reported prevalence range
from 1.9 to 3.8% [155]. The anticipated ageing of the
population (which is the main driver of dementia
figures) in Africa may translate in a higher prevalence
and absolute number of people living with dementia as
observed in other developing regions. However, caution
is needed when interpreting findings from studies con-
ducted in different settings by different investigators.
Our overview tends to suggest that the projected in-
crease in the prevalence of dementia in SSA is likely,
based on the comparison of findings from three recent
studies with those from the study above conducted in
Nigeria 20 years ago [55-57]. Furthermore, with the large
scale implementation of antiretroviral therapy and re-
lated improved survival, it is expected that the number
of patients with the diagnosis of HIV-related neurocog-
nitive impairment may increase as suggested by the in-
creasing number of related-publications. Such trends
will need to be confirmed by large scale prospective obser-
vational studies which will also assess the putative acceler-
ating effect of HIV-related neurocognitive impairment on
other types of prevalent dementia and neurodegeneration.
For Parkinsonism, the wide prevalence range observed
both in population and hospital-based studies might also
be a consequence of differences in methodologies for
case ascertainment, diagnostic criteria, or age distribu-
tions of the study populations. These heterogeneities in
PD prevalence are not unique to SSA as these have also
been observed in Europe where prevalence of PD ranged
from 66 to 12,500/100,000 [156]. There have been
provisional set of minimal scientific criteria for conduct-
ing epidemiological studies on PD which, when adopted
at a large scale will improve comparison within SSA and
between SSA and other regions of the world [156].
Prevalence rates reported in population-based studies in
the continent are limited to two studies and cases were
ascertained through screening and neurological exam in
one study, thus making any comparison with other
region difficult. In ALS and Huntington disease, the pic-
ture is less clear as the majority of studies were hospital-
based, retrospective in nature, with a final diagnosis not
always based on pathology or genetics and the risk
Table 5 Overview of studies on Huntington disease and risk factors in sub-Sahara African countries
Author, year of publication Country Setting Design/year of
the study
Population characteristics Diagnostic tool/criteria Prevalence
Hayden [141], 1977 South Africa Community Cross-sectional 26 cases (men 11); age 12–68 y. Clinical 3.5/100,000
Samuels [147], 1978 Zimbabwe Community Case series 1 family of HD Clinical NA
4 cases (men 2) age 14–26 y.
Glass [148], 1979 South Africa Community Case series 2 cases of HD (men 1) age 42-52 Clinical NA
Hayden [142], 1980 South Africa Community/hospital Cross-sectional, 481 cases (m en 241) of whom
153 (m en 69) alive by the time
of the study
Clinical Overall: 0.65/100,000,
Whites: 2.22/100,000,
Mixed ancestry:
2.17/100,000, Blacks:
0 · 01/100,000
Scrimgeour [149], 1981 Tanzania Community Case series 11 cases, aged 25–80 y. Clinical NA
Hayden [143], 1981 Mauritius Hospital Cross-sectional 2166 persons, 6 cases of HD (men 3) Not provided 46/100,000
Hayden [144], 1981 South Africa Hospital Cross-sectional/NR 17 children (onset before 20 y.)
identified during a national survey
among of 219 patients
Not provided Overall: 0.6/100,000
Whites: 0.37/100,000
Mixed ancestry:
0.89/100,000
Blacks: No case
Hayden [150], 1982 South Africa Community/hospital Cross-sectional 157 (men 71) individuals investigated
and 328 (women 156, only 3 negro-Africans)
deceased individuals with probably HD
Not specified Combined white and black
heterozygote frequency =
6 · 7 x 100,000
Scrimgeour [151], 1982 Tanzania Hospital Case series
(National registry)
7 patients with chorea (1 aged 80 y.) and
50 potential patients with chorea in
23 families
Not specified NA
Mean age at onset: 36 y.
Aiyesimoju [145], 1984 Nigeria Hospital Cross sectional
1957-1982
2.1 million patients admitted to
the hospital.
Not specified HD: 0.2/100,000
4 cases (men 3) of HD aged 24–50 y
at diagnosis.
Stephany [146], 1984 Senegal Hospital Cross sectional 12370 patients seen in a neurologic clinic; 3
(men 2) with HD; age 31–64 y.
Family history 24.2/100,000
All patients had
movement disorders
and neuropsychiatric
features
1960-1980
Joubert [136], 1988 South Africa Community/hospital Cross-sectional
1983-1986
8 cases in hospital setting (n = 6. all men)
and at home (n = 2);
Clinical/genetic
testing/screening
for Wilson disease
NA
Age at onset: 8–47 y.
Age at diagnosis: 13–50 y.
Lekoubou
et
al.BM
C
Public
H
ealth
2014,14:653
Page
25
of
32
http://w
w
w
.biom
edcentral.com
/1471-2458/14/653
Table 5 Overview of studies on Huntington disease and risk factors in sub-Sahara African countries (Continued)
Scrimgeour [152], 1992 Zimbabwe Hospital Case series1991 11 cases in a 4 generation of a single family;
2 probable cases
Clinical 0.5/100,000
Scrimgeour [153], 1995 Sudan Hospital Case-report 1 case of HD: A Clinical/MRI NA
40 year old black Sudanese man
Grunitzky [154], 1995 Togo Hospital Case series A family including 8 patients with HD and
67 at risk across 6 generations; mean age
at onset: 33 y.
Not specified NA
Silber [137], 1998 South Africa Community Case series 5 families of HD including a total of 7
genetically confirmed cases of HD and
10 clinically suspect cases of HD
Clinical/genetic
testing
NA
Kabore [138], 2000 Burkina-Faso Hospital Case series 4 cases of HD; age at diagnosis 33–43 y. Clinical/genetic
testing
0.04/100,000
Bardien [139], 2007 South Africa Hospital Case series
2001-2005
A family with HD like 2 Clinical/genetic
testing
1
Total 39 family members
13 had the disease
Magazi [140], 2008 South Africa Hospital Case series 12 cases (men 6); age 25–52 y. Clinical/genetic
testing
NA
HD; Huntington disease; MRI: magnetic resonance imaging; NA: not applicable; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association; y: year.
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and inferences inaccurate. For these two conditions
therefore, important gaps remain to be filled, without
which the issues of prevention and control will not be
efficiently addressed in the African context.
The comparatively higher number of population-based
investigations of dementia relative to other neurodegen-
erative conditions in SSA, may at least in part be ex-
plained by the availability of standardized and widely
accepted screening and diagnostic tools/criteria which
facilitate epidemiological studies of dementia [157] as
compared with other conditions where existing tools
have not always been validated in different settings and
therefore remain unpopular [158,159], or which, by the
virtue of their low prevalence makes any assessment in
the general population difficult and very expensive. There
are context-specific challenges to obtaining key epidemio-
logical data on neurodegenerative conditions in SSA in-
cluding the low level of patient education, the need to
accurately translate available screening and diagnostic
tools to local languages, limited number of scientists and
clinicians in neurosciences, and competing health interest
in the setting of limited financial resources [5,16].
Needs in terms of epidemiological data
In order to improve the knowledge base of each of the
neurodegenerative conditions addressed in this review,
two main types of epidemiological studies appear neces-
sary and feasible in SSA. A population-based prevalence
and incidence study including both urban and rural pop-
ulations, in order to capture the real variability in socio-
economic status and possibility in other factors that may
exist in the population. Such a study may serve a dual
purpose, providing information on disease rate and iden-
tification of key risk factors, as it would permit to estab-
lish the sequence of events. Given that such an
undertaking could be planned beforehand, it offers the
possibility of addressing multiple questions and/or dis-
eases at a reduced cost. Inclusion of a large enough but
manageable number of participants would be necessary
to ensure adequate precision around the estimates gen-
erated. As many patients with possible neurodegenera-
tive conditions would be tempted to consult traditional
healers rather than accessing health facilities in SSA,
special efforts would be required to ensure that these
people are captured by such a study. Also, ascertaining
cases of neurodegenerative conditions in a population-
based sample may be costly and logistically challenging,
particularly with regard to the asymptomatic or mildly
symptomatic nature of early stages of some of the dis-
eases, and the lack of validated instruments and appro-
priate expertise.
A second type of epidemiological study is a multicen-
ter, hospital-based, registry investigation. The latter hasseveral advantages over a single large-scale cohort study.
Large numbers of cases could potentially be collected
over a relatively short period of time, with the possibility
of comparing resources and outcomes within and across
countries. However, the major limitations of this ap-
proach include the costs associated with the effort and
infrastructure for coordination and communication be-
tween centers, as well as data capture and ongoing mon-
itoring and quality control. In addition, there are biases
inherent to any such hospital-based study, especially
given that in SSA there is major access and cost barriers
to care, with a sizeable proportion of patients with neu-
rodegenerative conditions who are never seen by health
care providers thus limiting the scope of registries. The
degree of such selection bias is likely to vary consider-
ably across centers, affecting both case mix and out-
comes. The approach would therefore not provide a
study population fully representative of incident cases
and the natural history of disease and its management.
For both types of studies, the definition of the pool of
people ‘at-risk’ population could be challenging in the
SSA context, given the lack of formal census of the
population in many countries; thus making reliable esti-
mation of the effect of individual risk factors difficult.
Other methodological issues relate to the assessment of
the outcome in a reliable fashion in the African context
as discussed above. Hence, a combination of the afore-
mentioned study approaches would probably overcome
some of their respective limitations and improve the
quality of estimates generated.
The challenges to performing high quality incidence
and prevalence studies of neurodegenerative diseases are
well known [159]. Cases of most neurodegenerative condi-
tions are difficult to define and ascertain reliably in
population-based sample, and there are problems in relat-
ing events and the effects of different exposures to defined
‘at-risk’ populations. With the ageing of the population in
SSA, the importance of HIV/AIDS, as well as the surge in
risk factors such as hypertension and diabetes that have
been linked to dementia [157,160,161] and possibly to
Parkinson diseases [162,163], the importance of neurode-
generative disorders would considerably increase over
time. Indeed, by 2025, the numbers of people aged 60 years
and over will more than double in many countries [164].
With this rapid demographic and nutritional transition,
neurodegenerative conditions would become an important
public health problem in SSA. Critical investments are
therefore necessary to improve surveillance and program-
relevant research to provide an evidence base for policy
development and effective control and prevention of neu-
rodegenerative diseases. Precise identification of risk fac-
tors other than ageing would allow proper prevention
effort spanning from primordial to secondary and event
tertiary prevention, given that most of those conditions
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risk of death. Community-based risk factor control, com-
bined with high risk approaches and realignment of health
systems to incorporate the chronic management of neuro-
degenerative diseases are needed.
Strengths and limitations of the review
Our review is the first of its kind on neurodegenerative
conditions in SSA. It is more up-to-date and broader
than previous attempts to summarize evidence on single
diseases in this setting [4-8]. By systematically assessing
all published articles on these conditions, we aimed to
draw the attention on the importance of the conditions
in the region, and identify the research priorities. A limi-
tation of this review is inherent to the limitations of the
individual studies included. We relied on clinic-based
studies where necessary in this systematic review; but
such studies have limitations, particularly with regard to
the generalization of their results data. However, we have
tried to convey a clear understanding of the current bur-
den and risk factors of each condition by examining all
published papers across a broad range of clinical, biol-
ogy, public health, and psychosocial literature, incorpor-
ating various types of evidence. By the nature of the
disease, the age range for participants in studies on ALS
and HIV-related neurocognitive impairment extended to
the pediatric age for some studies. It is of note that large
number of studies are realized in hospital in Africa,
often published in local journals or reported in thesis. It
the absence of straightforward strategies for capturing
this sort of evidence in a systematic way, we did not ac-
count for them, which may have lowered the number of
results found in some countries. Finally, the many
sources of heterogeneity precluded any meaningful
assessed of the quality of the included studies.
Conclusion
This review summarizes the body of literature on neuro-
degenerative disorders in SSA, which is large with regard
to Dementia and HIV-related neurocognitive disorders
but limited for other neurodegenerative disorders. In
addition, it emphasizes some of the challenges in con-
ducting good quality, population-based studies on the
continent including the lack of standardized criteria for
some neurodegenerative disorders, with most studies
limited to few regions/countries on the continent. High-
quality prospective cohort studies, which would use
internationally- validated criteria, wide catchment areas
in several geographic regions, and adjust for the pro-
jected ageing of the continent population, by compensat-
ing for the imprecise nature of the available data, will
help map the epidemiology of neurodegenerative dis-
eases in SSA and improve comparisons with the rest of
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